Galmed pharmaceuticals reports first quarter 2025 financial results and provides business update

Tel aviv, israel , may 22, 2025 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and gi oncological indications, reports financial results for the three months ended march 31, 2025 and recent developments.
GLMD Ratings Summary
GLMD Quant Ranking